Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Latest filing published 01 Sept 2026 for Crinetics Pharmaceuticals, Inc., €434k. Read the official filing
Filing timeline
BuySaleMatthew K. Fust
Insider track record
Disclosed buys
0
Disclosed sells
3
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Matthew K. Fust: trading record in brief
Matthew K. Fust, listed as board member, has filed trades across 4 companies (mainly through SEC (Form 4)), most often in Crinetics Pharmaceuticals, Inc., Atara Biotherapeutics, Inc. and Ultragenyx Pharmaceutical Inc. We count 31 filings; the first trade dates from 8 June 2021 and the latest from 1 September 2026.
On the market, this insider has only sold: 3 sales, €957k in total. Besides market trades, the filings include 16 share grants and 10 option exercises.
On 1 September 2026 came the latest disclosure, a transaction for €1.7M in Crinetics Pharmaceuticals, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Matthew K. Fust
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations31 total
5,925 shares@ US$85.000.0056% mcap14.2% of flowCommon StockSEC:0001628280-26-059902:1
22,836 shares@ US$85.000.022% mcap54.6% of flowCommon StockSEC:0001628280-26-059902:0
5,925 sharesCommon StockSEC:0001628280-26-044717:0
12,000 sharesCommon StockSEC:0000905148-26-002920:0
10,000 shares@ US$1.911.6% of flowCommon StockSEC:0001658247-25-000010:0
16,000 shares@ US$44.7561.2% of flowCommon StockSEC:0001658247-25-000010:1
6,900 shares0Common StockSEC:0000950170-25-086266:0
7,828 shares0Common StockSEC:0000905148-25-002141:0
5,740 shares0Common StockSEC:0000950170-25-074664:0
3,783 shares@ US$8.32100.0% of flowCommon StockSEC:0001610717-24-000511:0
5,345 shares0Common StockSEC:0000950170-24-075489:0
20,100 shares0Common StockSEC:0001610717-24-000335:0
3,400 shares0Common StockSEC:0000950170-24-071924:0
150,000 shares0Common StockSEC:0000905148-24-001060:0
12,500 shares@ US$23.2426.6% of flowCommon StockSEC:0001209191-24-005060:0
2,550 shares@ US$50.8930.3% of flowCommon StockSEC:0000950170-24-029040:0
6,000 shares0Common StockSEC:0001209191-23-038819:0
3,860 shares0Common StockSEC:0001209191-23-035691:0
57,000 shares0Common StockSEC:0001140361-23-028152:0
5,700 shares@ US$1.450.8% of flowCommon StockSEC:0001209191-22-042245:0
3,300 shares0Common StockSEC:0001209191-22-039566:0
20,500 shares0Common StockSEC:0001140361-22-024164:0
7,500 shares@ US$40.3769.7% of flowCommon StockSEC:0001209191-22-016930:0
13,354 shares@ US$19.50100.0% of flowCommon StockSEC:0001567619-21-019403:0
8,954 shares@ US$1.911.5% of flowCommon StockSEC:0001209191-21-062728:0
25 of 31 declarations
